SURF News and Press, Surface Oncology Inc. From 04/27/21

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and ...

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology , a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of th...

Surface Oncology (SURF) will present preclinical findings supporting its lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39) at the American Association for Cancer Research ((AACR)) 2021 Annual Meeting.Presentation summaries are as follows: SRF617 is a potent inhi...

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead produc...

Shares of Surface Oncology (NASDAQ: SURF) had soared by 11.3% as of 10:44 a.m. EDT on Wednesday. The big gain came after the company announced late on Tuesday that the Food and Drug Administration had granted an orphan drug designation to its candidate drug SRF617 as a potential tre...

Regulatory approvals are big wins for biotech companies. It is no different for cancer drug specialist Surface Oncology (NASDAQ: SURF) , the shares of which were up nearly 13% in early after-hours trading Tuesday following an important nod from the U.S. Food and Drug Administration ...

Gainers: [[ELOX]] +19.9%. [[SURF]] +15.0%. [[EVK]] +14.3%. [[EQ]] +10.4%. [[HYFM]] +9.2%.Losers: [[EDAP]] -7.4%. [[IMVT]] -5.3%. [[BYND]] -4.8%. [[CRMD]] -4.8%. [[OSMT]] -3.7%. For further details see: ELOX, SURF, EDAP and IMVT among after-hours movers

Surface Oncology (SURF) announces that the U.S. FDA has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.Programs with Orphan Drug status receive partial tax credit for clinical trial...

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Surface Oncology ([[SURF]] +3.2%) is on the rise amid rumors that Cathie Wood will talk about the company at a conference scheduled for today.The stock has lost ~4.5% in the year so far, and ARK Genomic Revolution ETF ([[ARKG]] -2.0%) managed by the acclaimed fund manager has a ~0.4% ...